tiprankstipranks
Trending News
More News >
Camurus AB (SE:CAMX)
:CAMX

Camurus AB (CAMX) Price & Analysis

Compare
0 Followers

CAMX Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

4.41%93.10%
Insiders
4.41%
Mutual Funds
― Other Institutional Investors
93.10% Public Companies and
Individual Investors

CAMX FAQ

What was Camurus AB’s price range in the past 12 months?
Camurus AB lowest stock price was kr483.80 and its highest was kr715.00 in the past 12 months.
    What is Camurus AB’s market cap?
    Camurus AB’s market cap is kr36.22B.
      When is Camurus AB’s upcoming earnings report date?
      Camurus AB’s upcoming earnings report date is Jul 17, 2025 which is in 19 days.
        How were Camurus AB’s earnings last quarter?
        Camurus AB released its earnings results on May 15, 2025. The company reported kr3.35 earnings per share for the quarter, beating the consensus estimate of kr2.917 by kr0.433.
          Is Camurus AB overvalued?
          According to Wall Street analysts Camurus AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Camurus AB pay dividends?
            Camurus AB does not currently pay dividends.
            What is Camurus AB’s EPS estimate?
            Camurus AB’s EPS estimate is 3.27.
              How many shares outstanding does Camurus AB have?
              Camurus AB has 59,626,984 shares outstanding.
                What happened to Camurus AB’s price movement after its last earnings report?
                Camurus AB reported an EPS of kr3.35 in its last earnings report, beating expectations of kr2.917. Following the earnings report the stock price went down -12.55%.
                  Which hedge fund is a major shareholder of Camurus AB?
                  Currently, no hedge funds are holding shares in SE:CAMX

                  Company Description

                  Camurus AB

                  Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

                  CAMX Company Deck

                  CAMX Earnings Call

                  Q1 2025
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The earnings call presented strong financial performance and growth in key product sales, along with a solid cash position. However, challenges such as the FDA's CRL and increased operating expenses were noted. The positive aspects of growth and profitability were more pronounced, leading to an optimistic outlook.Read More>
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Hansa Biopharma AB
                  BioArctic AB Class B
                  Xbrane Biopharma AB
                  Xspray Pharma AB
                  SynAct Pharma AB
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis